NCT01483638终止2 期
A Phase II Study of Axitinib as Maintenance Treatment for Patients With Metastatic Colorectal Carcinoma
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2012年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- progression-free survival
研究概览
简要总结
The purpose of this study is to evaluate the maintenance therapy with axitinib in patients with metastatic colorectal carcinoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have histological or cytological confirmed colorectal adenocarcinoma with metastatic disease documented on diagnostic imaging studies, not susceptible of radical surgery of metastases, and a low burden of disease.
- •Patients without progressive disease after six months of the standard first line chemotherapy regimen for CRC (5FU or capecitabine ± oxaliplatin or irinotecan ± bevacizumab or cetuximab).
- •Patient must have at least one measurable lesion as defined by modified RECIST criteria.
- •Male or female, age ≥18 years.
- •ECOG performance status of 0 or 1 and life expectancy of ≥12 weeks.
- •Adequate organ function as defined by the following criteria:
- •absolute neutrophil count (ANC) ≥1500 cells/mm3;
- •platelets ≥100,000 cells/mm
- •Hemoglobin ≥9.0 g/dL.
- •AST and ALT ≤2.5 x upper limit of normal (ULN), unless there are liver metastases in which case AST and ALT ≤5.0 x ULN;
- •Total bilirubin ≤1.5 x ULN;
- •Alkaline phosphatase <300U/l
- •Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥50 mL/min;
- •Urinary protein <2+ by urine dipstick. If dipstick is ≥2+ then a 24-hour urine collection can be done and the patient may enter only if urinary protein is <2 g per 24 hours.
- •At least 4 weeks since the end of prior systemic treatment, radiotherapy, or surgical procedure with resolution of all treatment-related toxicity to NCI CTCAE Version 4.0 grade ≤1 or back to baseline except for alopecia or neurotoxicity
- •No evidence of pre existing uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. The baseline systolic blood pressure readings must be ≤140 mm Hg, and the baseline diastolic blood pressure readings must be ≤90 mm Hg. Patients whose hypertension is controlled by antihypertensive therapies are eligible.
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment.
- •Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment.
- •Willingness and ability to comply with scheduled visits, treatment plans (including willingness to take either AG-013736 or placebo according to randomization), laboratory tests, and other study procedures.
排除标准
- •Gastrointestinal abnormalities including:
- •inability to take oral medication;
- •requirement for intravenous alimentation;
- •prior surgical procedures affecting absorption including total gastric resection;
- •treatment for active peptic ulcer disease in the past 6 months;
- •active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;
- •malabsorption syndromes.
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to start, unless affected area has been removed surgically
- •Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors (ie, grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir and delavirdine).
- •Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (ie, carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampin, and St. John's wort).
- •History of haemorrhage within the past 6 months, including gross hemoptysis or hematuria.
- •Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed.
- •Active seizure disorder or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis.
- •A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment.
- •Any of the following within the 12 months prior to study drug administration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism.
- •Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any grade, or QTc interval >450 msec for males or >470 msec for females.
- •Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
- •History of a malignancy (other than colorectal cancer) except those treated with curative intent for skin cancer (other than melanoma), in situ breast or in situ cervical cancer, or those treated with curative intent for any other cancer with no evidence of disease for 2 years.
- •Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.
- •Female patients who are pregnant or lactating, or men and women of reproductive potential not willing or not able to employ an effective method of birth control/contraception to prevent pregnancy during treatment and for 6 months after discontinuing study treatment. The definition of effective contraception should be in agreement with local regulation and based on the judgment of the principal investigator or a designated associate.
- •Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
- •Current, recent (within 4 weeks of the study treatment administration), or planned participation in an experimental therapeutic drug study other than this protocol.
研究组 & 干预措施
control
Placebo Comparator
placebo
干预措施: placebo (Drug)
Experimental
Experimental
axitinib
干预措施: axitinib (Drug)
结局指标
主要结局
progression-free survival
时间窗: 4 years
次要结局
- overall survival(4 years)
- overall response rate(4 years)
- duration of disease response(4 years)
- Adverse events(4 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase II study of Axitinib as maintenance for patients with advanced colorectal carcinoma.Advanced colorectal carcinomaMedDRA version: 14.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002384-16-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)49
已完成
2 期
Study of Axitinib in Patients With Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT01334112University Health Network, Toronto30
已完成
2 期
A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue SarcomasSoft Tissue SarcomaNCT01140737Sheffield Teaching Hospitals NHS Foundation Trust145
已完成
2 期
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaAdenoid Cystic CarcinomaNCT01558661Memorial Sloan Kettering Cancer Center33
已完成
2 期
A Study of Axitinib in Advanced Carcinoid TumorsCarcinoid TumorNCT01435122H. Lee Moffitt Cancer Center and Research Institute30